MedTrace Logo

A Trial of Pembrolizumab for Refractory Atypical and Anaplastic Meningioma

NCT03016091 · Status: TERMINATED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 18

Last updated 2025-02-18

Study results available
· View outcomes & findings →

Summary

A Phase II, Open-label, Single Arm Trial of Pembrolizumab for Refractory Atypical and Anaplastic Meningioma

Conditions

  • Atypical Meningioma
  • Anaplastic Meningioma
  • Hemangiopericytoma

Interventions

DRUG

Pembrolizumab

anti PD-L1

Sponsors & Collaborators

  • Rabin Medical Center

    lead OTHER

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
85 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-01-01
Primary Completion
2022-07-01
Completion
2022-12-01

Countries

  • Israel

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03016091 on ClinicalTrials.gov